Synthesis, characterization, molecular docking, and in vitro antidiabetic activity studies of new and highly selective methoxy-substituted benzimidazole

Abstract

The benzimidazole-based new therapeutic agent has been efficiently synthesized using one pot condensation-cyclization reaction method involving 1,2-phenylenediamine, and benzaldehyde under mild condition and characterized by different analytical tools such as NMR, Mass, and FT-IR spectroscopy. This compound has employed a protein inhibition assay for the in-vitro antidiabetic and anti-inflammation activity. The obtained data are compared with standard drug molecules. This activity has been correlated with molecular docking studies with three protein molecules for diabetes and inflammations. The structure of the compound was confirmed by the single-crystal XRD method. In addition, the theoretical method is also used as supporting data for its activity towards diabetic and inflammatory activity. The FMO, MEP, and Mulliken charge distribution have been made using DFT analysis, and various reactive parameters are calculated using HOMO and LUMO. The benzimidazole-based TBTPBI has experimented with antidiabetic and anti-inflammatory activity in-vitro manner using protein inhibition and denature techniques. A perfect correlation was found between DFT and the biological screening of TBTPBI with less binding energies and higher inhibition constants values.